OBJECTIVES: Although NSCLC is associated with substantial symptom burden and significantly impacts patients’ health-related quality of life (HRQoL), published data from routine care are scarce. Improving the understanding of the HRQoL impact of NSCLC will allow to comprehend more in-depth the benefit of treatments, palliative care and differing HRQOL accross health states.   METHODS: A total 315 patients were enrolled in Australia, Belgium, Canada, France, Italy, Sweden, Turkey, the Netherlands and the UK to complete the EQ-5D and EQ-VAS questionnaires after receiving current treatment for 6-8 weeks. In order not to influence patients’ perceived health, patients completed the questionnaire prior to receiving information on their tumor status. Patient demographic, disease history, treatment and adverse event data was identified from the patient chart. Utilities were calculated by applying the UK tariffs. Patients were stratified into 12 health states based on treatment line and treatment response status. Patients included had advanced stage (IIIb or IV) disease, were ≥18 years, received 1-4 lines of treatment having an ECOG performance status of 0-2 (scale: 0-4 with 4 being bedridden). RESULTS: Mean age at advanced NSCLC diagnosis was 64.5 years [SD=9.97] with 61.8% of patients being male, and 80.3% with stage IV disease. Fifty-two percent, 27%, and 19% of patients were on 1st, 2nd, or 3rd/4th line, respectively. Patients with progressive disease increased with treatment line; 15% (1st line), 27% (2nd line) and 46% (3rd/4th line). Mean utility in the overall sample was 0.65 [SD=0.31]. Mean utility for progression free patients on 1st, 2nd, and 3rd/4th line treatment was 0.71 [SD=0.24], 0.72 [SD=0.26], and 0.62 [SD=0.46], respectively. Mean utility for patients who progressed after 1st, 2nd and 3rd/4th line treatment was 0.68 [SD=0.21], 0.59 [SD=0.34] and 0.46 [SD=0.38], respectively. CONCLUSIONS: Both line of treatment and progressive NSCLC disease were found to impact patients’ HRQoL assessed using EQ-5D derived utilities.